
|Videos|March 15, 2017
High Cost Impacts PCSK9 Inhibitor Access
Author(s)Lauren Santye, Assistant Editor
Mark Tesell, PharmD, BCPS, discusses how the high cost of PCSK9 inhibitors effected uptake of the cholesterol-lowering drug.
Advertisement
Mark Tesell, PharmD, BCPS, discusses how the high cost of PCSK9 inhibitors effected uptake of the cholesterol-lowering drug.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Tradipitant Becomes First Treatment Approved for Vomiting Due to Motion Sickness in 4 Decades
2
Psychiatric Pharmacists Take a Larger Role in Substance Use Disorder Care
3
Aspirin Dosage and Decision-Making: What Pharmacists Should Know
4
Expanding Access to MOUD: The Psychiatric Pharmacist’s Role in Optimization
5












































































































































































































